The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance
- PMID: 31202693
- DOI: 10.1016/j.bbagen.2019.06.007
The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance
Abstract
Background: Multi-drug resistance (MDR) is a leading cause of morbidity and mortality in cancer and it continues to be a challenge in cancer treatment. Moreover, the tumor micro-environment is essential to the formation of drug resistant cancers. Recent evidence indicates that the tumor micro-environment is a critical regulator of cancer progression, distant metastasis and acquired resistance of tumors to various therapies. Despite significant advances in chemotherapy and radiotherapy, the development of therapeutic resistance leads to reduced drug efficacy.
Scope of review: This review highlights mechanistic aspects of the biochemistry of the tumor micro-enviroment, such as the hypoglycaemia, reactive oxygen species (ROS), hypoxia and their effects in propagating MDR. This is achieved through: (A) increased survival via autophagy and failure of apoptosis; (B) altered metabolic processing; and (C) reduction in drug delivery and uptake or increased drug efflux.
Major conclusions: The development of MDR in cancer has been demonstrated to be majorly influenced by naturally occurring stressors within the tumor micro-environment, as well as chemotherapeutics. Thus, the tumor micro-environment is currently emerging as a major focus of research which needs to be carefully addressed before cancer can be successfully treated.
General significance: Elucidating the biochemical mechanisms which promote MDR is essential in development of effective therapeutics that can overcome these acquired defences in cancer cells.
Keywords: Apoptosis; Autophagy; Hypoxia; Metabolism; Multi-drug resistance; Tumor micro-environment.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Tumour Microenvironment Stress Promotes the Development of Drug Resistance.Antioxidants (Basel). 2021 Nov 11;10(11):1801. doi: 10.3390/antiox10111801. Antioxidants (Basel). 2021. PMID: 34829672 Free PMC article. Review.
-
Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?Mol Pharm. 2014 Aug 4;11(8):2527-38. doi: 10.1021/mp500066v. Epub 2014 Jun 20. Mol Pharm. 2014. PMID: 24921216 Review.
-
The multi-factorial nature of clinical multidrug resistance in cancer.Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17. Drug Resist Updat. 2019. PMID: 31585396 Review.
-
The role of tumor microenvironment in therapeutic resistance.Oncotarget. 2017 Jan 17;8(3):3933-3945. doi: 10.18632/oncotarget.13907. Oncotarget. 2017. PMID: 27965469 Free PMC article. Review.
-
The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer.Curr Pharm Des. 2024;30(35):2765-2784. doi: 10.2174/0113816128326325240723051625. Curr Pharm Des. 2024. PMID: 39113303 Review.
Cited by
-
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer.Cancers (Basel). 2020 Feb 4;12(2):352. doi: 10.3390/cancers12020352. Cancers (Basel). 2020. PMID: 32033142 Free PMC article. Review.
-
Drug Delivery Systems of Natural Products in Oncology.Molecules. 2020 Oct 6;25(19):4560. doi: 10.3390/molecules25194560. Molecules. 2020. PMID: 33036240 Free PMC article. Review.
-
Glycemic load impacts the response of acquired resistance in breast cancer cells to chemotherapeutic drugs in vitro.PLoS One. 2024 Nov 22;19(11):e0311345. doi: 10.1371/journal.pone.0311345. eCollection 2024. PLoS One. 2024. PMID: 39576770 Free PMC article.
-
Kinetics of Nanomedicine in Tumor Spheroid as an In Vitro Model System for Efficient Tumor-Targeted Drug Delivery With Insights From Mathematical Models.Front Bioeng Biotechnol. 2021 Dec 1;9:785937. doi: 10.3389/fbioe.2021.785937. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34926430 Free PMC article. Review.
-
Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1).J Med Chem. 2023 Jan 12;66(1):657-676. doi: 10.1021/acs.jmedchem.2c01612. Epub 2022 Dec 30. J Med Chem. 2023. PMID: 36584238 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials